The emergence of Retatrutide ZPHC, at a concentration of 120mg, is sparking considerable buzz within the medical community. This novel dual GIP and GLP-1 receptor medication suggests to offer impressive improvements in fat loss compared to current therapies. Initial patient studies have indicated